Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 3/20 | 0.41 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534780 | 1.00 | TACR1 (0.48) | TACR1EGFRLCKCDK1ERN1 | |
| SCHEMBL7247841 | 0.90 | LCK (0.54) | TACR1LCKCDK1ERN1XDH | |
| SCHEMBL13588693 | 0.85 | TACR1 (0.52) | TACR1EGFRLCKTP53CA2 | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL468756 | 0.79 | TACR1 (0.58) | TACR1 | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL14370511 | 0.79 | TACR1 (0.58) | TACR1 | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL468858 | 0.79 | TACR1 (0.58) | TACR1 | |
| SCHEMBL13588694 | 0.79 | TACR1 (0.48) | TACR1EGFRLCK | |
| SCHEMBL6224832 | 0.78 | TACR1 (0.53) | TACR1LCKTP53 | |
| SCHEMBL3282594 | 0.78 | TACR1 (0.53) | TACR1LCKTP53 | |
| Acetyl Tyrosine Ethyl Ester SCHEMBL25257912 | 0.78 | TACR1 (0.56) | TACR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007076-A4 | METHOD OF ANTAGONIZING THE HUMAN SRC SH2 DOMAIN | SMITHKLINE BEECHAM CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030096760-A1 | Method of antagonizing the human SRC SH2 domain | SMITHKLINEBEECHAM CORPORATION | 2003-05-22 | — | — | US | disclosed |
| EP-1007076-A1 | METHOD OF ANTAGONIZING THE HUMAN SRC SH2 DOMAIN | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998040093-A1 | METHOD OF ANTAGONIZING THE HUMAN SRC SH2 DOMAIN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096760-A1 | Method of antagonizing the human SRC SH2 domain | SRC, CTTN, LCK | TACR1 2233/4885EGFR 171/4885LCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.